Zobrazeno 1 - 10
of 36
pro vyhledávání: '"José Luis, Herrera Garza"'
Autor:
José Carlos Jaime-Pérez, Gisela García-Arellano, José Luis Herrera-Garza, Luis Javier Marfil-Rivera, David Gómez-Almaguer
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 41, Iss 1, Pp 57-61 (2019)
Background: Heterogeneity regarding clinical and laboratory findings at diagnosis of acute lymphoblastic leukemia exists. The frequency of complete blood count abnormalities and its combinations, symptoms and physical findings were investigated in Hi
Externí odkaz:
https://doaj.org/article/dcfb97207bb34061a48f355742ebfea8
Autor:
José Carlos Jaime-Pérez, Teresa A. Nava-Obregón, David Gómez-Almaguer, José Luis Herrera-Garza, Olga G. Cantú-Rodríguez, Grecia A. Turrubiates-Hernández, Homero Gutiérrez-Aguirre, Blanca Coronado-Hernández
Publikováno v:
American Journal of Hospice and Palliative Medicine®. 37:600-605
Background: Palliative care (PC) for patients with malignant hematological diseases is scarcely documented, particularly in low- and middle-income countries. This study aimed to document PC provided to patients with hematologic malignancies. Methods:
Autor:
Ernesto Picón-Galindo, David Gómez-Almaguer, José Luis Herrera-Garza, José Carlos Jaime-Pérez
Publikováno v:
Hematological oncologyREFERENCES. 39(1)
Relapse and graft failure after autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT) are serious and frequently fatal events. A second HSCT can be a life-saving alternative, however, information on the results of such
Autor:
José Luis Herrera-Garza, Patrizia Aguilar-Calderón, José Carlos Jaime-Pérez, David Gómez-Almaguer, Lorena Salazar-Cavazos, César Homero Gutiérrez-Aguirre
Publikováno v:
Bone Marrow Transplantation. 54:828-838
Efficacy of an ambulatory hematopoietic stem cell transplant (HSCT) program with a reduced intensity conditioning regimen (RIC) in malignant hematological diseases was assessed. We analyzed 217 patients who underwent HSCT from August 2013 to July 201
Autor:
José Luis Herrera-Garza, Lucía T. Fernández, David Gómez-Almaguer, José Ramón Padilla-Medina, Luz Tarín-Arzaga, César Homero Gutiérrez-Aguirre, José Carlos Jaime-Pérez
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:286-292
Introduction The outcomes for adolescents and young adults (AYAs) with acute myeloid leukemia (AML) have been poorly characterized in Hispanics in low- to middle-income countries. The results are influenced by biologic and socioeconomic factors. The
Autor:
Luis Javier Marfil-Rivera, José Carlos Jaime-Pérez, David Gómez-Almaguer, Gisela García-Arellano, José Luis Herrera-Garza, Grecia A. Turrubiates-Hernández
Publikováno v:
Revista Medicina Universitaria. 21
Autor:
David Gómez-Almaguer, Luis Javier Marfil-Rivera, José Carlos Jaime-Pérez, Gisela García-Arellano, José Luis Herrera-Garza
Publikováno v:
Hematology, Transfusion and Cell Therapy, Volume: 41, Issue: 1, Pages: 57-61, Published: 15 APR 2019
Hematology, Transfusion and Cell Therapy, Vol 41, Iss 1, Pp 57-61 (2019)
Hematology, Transfusion and Cell Therapy
Hematology, Transfusion and Cell Therapy, Vol 41, Iss 1, Pp 57-61 (2019)
Hematology, Transfusion and Cell Therapy
Background: Heterogeneity regarding clinical and laboratory findings at diagnosis of acute lymphoblastic leukemia exists. The frequency of complete blood count abnormalities and its combinations, symptoms and physical findings were investigated in Hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::671ba61b8054980d55ddbe5e82f92e68
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792019000100057&lng=en&tlng=en
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792019000100057&lng=en&tlng=en
Autor:
José Luis Herrera-Garza, Cesar Daniel Villarreal-Villarreal, David Gómez-Almaguer, Olga G. Cantú-Rodríguez, Alberto Carlos Heredia-Salazar, Homero Gutiérrez-Aguirre, José Carlos Jaime-Pérez, Consuelo Mancías-Guerra
Publikováno v:
The Oncologist. 20:386-392
Background and Objective. Hematopoietic stem cell transplantation (HSCT) in developing countries is cost-limited. Our primarygoalwastodeterminethecoststructurefortheHSCT program model developed over the last decade at our public university hospital a
Autor:
Homero Gutiérrez-Aguirre, David Gómez-Almaguer, Karina Selene Martínez-de la Garza, José Luis Herrera-Garza, Alfonso Reyes-Escobedo, José Carlos Jaime-Pérez, Olga G. Cantú-Rodríguez
Publikováno v:
Nutrition and Cancer. 66:924-929
The relationship between treatment for hematologic malignancies and risk of developing metabolic syndrome (MS) is controversial; in addition, metabolic changes following hematopoietic stem cell transplantation (HSCT) is an area of growing interest. W